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Open Forum Infectious Diseases
MAJOR ARTICLE

Controlled Human Hookworm Infection: Accelerating
Human Hookworm Vaccine Development
David Diemert,1,2 Doreen Campbell,1 Jill Brelsford,1 Caitlyn Leasure,1 Guangzhao Li,1 Jin Peng,1 Maria Zumer,2 Naji Younes,3 Maria Elena Bottazzi,4
Rojelio Mejia,4 David I. Pritchard,5 John M. Hawdon,1,* and Jeffrey M. Bethony1,*
1

Department of Microbiology, Immunology and Tropical Medicine, 2Department of Medicine, and 3Milken Institute School of Public Health, The George Washington University, Washington DC;
Department of Pediatrics, Section of Pediatric Tropical Medicine, Texas Children’s Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine,
Houston, Texas; 5Department of Pharmacy, University of Nottingham, Nottingham, United Kingdom

4

Background. Controlled human hookworm infection (CHHI) is a central component of a proposed hookworm vaccination-challenge model (HVCM) to test the efficacy of candidate vaccines. Critical to CHHI is the manufacture of Necator americanus
infective larvae (NaL3) according to current Good Manufacturing Practice (cGMP) and the determination of an inoculum of NaL3
that is safe and reliably induces patent infection.
Methods. cGMP-grade NaL3 were produced for a phase 1 trial in 20 healthy, hookworm-naïve adults in the United States, who
received either 25 or 50 NaL3. Participants were monitored for 12–18 weeks postinfection for safety, tolerability, and patency of
N. americanus infection.
Results. Both NaL3 doses were well tolerated. Early manifestations of infection included pruritus, pain, and papulovesicular
rash at the application site. Gastrointestinal symptoms and eosinophilia appeared after week 4 postinfection. The 50 NaL3 inoculum
induced patent N. americanus infection in 90% of this dose group.
Conclusions. The inoculum of 50 NaL3 was well tolerated and consistently induced patent N. americanus infection suitable for
future HVCM trials.
Clinical Trials Registration. NCT01940757.
Keywords. challenge model; controlled human hookworm infection; current good manufacturing practice; hookworm vaccine;
Necator americanus.

More than 400 million individuals are infected with hookworms,
hematophagic nematodes that parasitize the host gastrointestinal
tract [1]. Chronic hookworm infection can induce iron deficiency
anemia, with children and women of childbearing age being most
at risk [2]. Current control efforts rely on mass drug administration (MDA) with a benzimidazole (BZ) that cures established
infections but does not prevent re-infection [3]. Furthermore,
development of resistance to BZs, as seen in livestock [4, 5], is a
significant concern. Given the limitations of MDA, a preventative
human hookworm vaccine (HHV) is being developed. The current HHV candidate antigens, Na-GST-1 and Na-APR-1, have
been evaluated in clinical trials in the United States, Brazil, and
Gabon and have been found to be safe and immunogenic [6, 7].
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The next stage of clinical development for the HHV is to
assess vaccine efficacy, which conventionally requires costly
field trials in Necator-endemic areas, with large sample sizes
(~1200 volunteers) and lengthy duration (1–2 years) [8]. To
mitigate the expense and risk of such trials, we propose a hookworm vaccination-challenge model (HVCM) to provide early
proof of concept of vaccine efficacy that would entail immunizing hookworm-naïve adults from nonendemic areas with candidate vaccines and then challenging them with infective Necator
americanus larvae (NaL3). Efficacy would be determined by the
absence of patent infection (no detectable eggs in feces) or a
reduction in infection intensity (expressed by eggs per gram
[EPG] of feces) compared with unvaccinated controls [7, 9, 10].
Although hookworm-naïve volunteers have been infected
with N. americanus in prior studies [11–20], we report the
first trial in which NaL3 produced according to current Good
Manufacturing Practice (cGMP) were administered to healthy
volunteers to determine the tolerability of different doses and to
establish an effective inoculum for future HVCM trials.
METHODS
cGMP Manufacture of NaL3

Necator americanus larvae were manufactured by the
Immune Modulation Research Group (IMRG) at the
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University of Nottingham, United Kingdom, under an
Investigational Medicinal Product Dossier from the UK
Medicines and Healthcare products Regulatory Agency
(UK MIA [IMP] 3057). Briefly, feces were collected from a
chronically infected volunteer who was screened for communicable agents considered relevant for topically applied
investigational medicinal products, per 21CFR§1271.3(r)
(1) (Supplementary Methods). Fecal material was mixed
with amphotericin B and gentamicin for 6 hours, to which
activated charcoal (Fisher Scientific, Loughborough, UK)
was added, and incubated for 10 days at 28ºC according to
a modified Harada Mori method to recover NaL3 [21, 22].
Recovered NaL3 were isolated and washed repeatedly in sterile water. NaL3 batches were tested for viability (motility), identity (lectin-binding assay), and microbial contamination (USP
<61> and <62>, and then released by IMRG (Supplementary
Methods) and transported to George Washington University
(GWU) at 19ºC–25ºC in a temperature-monitored container.
Microbial contamination was retested according to USP <61>
and <62>) for total aerobic microbial and combined yeast and
mold counts, as well as the absence of Staphylococcus aureus
and Pseudomonas aeruginosa, after arrival at GWU and prior
to application in the clinical trial under an US Food and Drug
Administration (FDA) Investigational New Drug (IND) application (#015752).
Study Design

The phase 1 trial (NCT01940757) was an open-label dose
escalation study of 20 healthy, hookworm-naïve adults aged
18–45 years at the George Washington University (Washington,
DC). In Cohort 1, 10 volunteers received an inoculum of 25
NaL3; in Cohort 2, they received 50 NaL3. NaL3 were pipetted
onto a sterile gauze pad, which was applied to the volar aspect
of the forearm and covered with an adhesive bandage for 1 hour.
After removal, the gauze was placed into sterile water to count
residual NaL3.
Cohorts were enrolled in a staggered fashion, with at least 8
weeks of safety data assessed by a Safety Monitoring Committee
prior to dose escalation. Participants were evaluated 3, 7, 14,
and 28 days postinfection (p.i.) and then weekly until treatment with 3 daily doses of 400 mg albendazole on day 84 for the
first 14 participants, and on day 126 for the last 6. At each visit,
application sites were examined for erythema, swelling, and
tenderness. Solicited symptoms included fever, abdominal pain
or bloating, nausea, vomiting, diarrhea, cough, and sore throat.
Participants completed daily symptom diaries for the duration
of their infections.
Adverse events were graded as mild (easily tolerated), moderate (interfered with activities of daily living), or severe (prevented activities of daily living) and assigned causality relative
to NaL3. Complete blood counts were performed prior to
NaL3 application and at regular time points starting at week 5
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(Supplementary Methods). The study was approved by the
GWU Institutional Review Board (IRB), and written informed
consent was obtained from all volunteers. Inclusion and exclusion criteria are listed in the Supplementary Methods.
Detection of Patency

Beginning 5 weeks p.i., fecal samples were examined weekly
by both saline flotation and quantitative polymerase chain
reaction (qPCR) methods to detect N. americanus eggs [10].
Samples were further analyzed by the McMaster (MM) technique and qPCR to assess intensity of infection, expressed as
EPG of feces [9].
Statistical Analysis

Time to patent infection was displayed using Kaplan-Meier
estimates, with log-rank tests used to compare the distribution of time to patency between dose groups and censoring of
early withdrawals or those failing to develop patent infection.
Proportions with patent infection were compared between dose
groups by the Fisher exact test. Locally weighted regression was
used to display trends in eosinophil counts and fecal EPGs by
study day. Mann-Whitney U tests were used to evaluate differences in EPG and eosinophil counts between dose groups and
study day. Sign tests were used to determine if median eosinophil counts were above the upper limit of the normal range.
A Cox proportional hazards model was used to evaluate the
effects of covariates (eg, NaL3 dose or eosinophil count) on
time to patency. A generalized linear mixed-effects model was
constructed using the PROC GLIMMIX procedure to determine the effects of eosinophil count and NaL3 dose on EPG
levels quantified by MM or qPCR. To compare the accuracy
of infection intensity, as measured by MM and qPCR, signed
rank tests were used to evaluate differences between EPG determined by the 2 methods. Receiver operating characteristic
(ROC) curves were used to compare the accuracy of MM and
qPCR in discriminating between patency and no patency, with
the saline flotation method used as the gold standard. Analyses
were conducted using SAS, version 9.3 (Cary, NC), and figures
were constructed using R software (version 3.3.2).
Power Calculations for HVCM

Data from the current study were used to calculate the sample
sizes required for the HVCM. Primary sample size analysis was
based on comparing the proportion of individuals with patent
infection in the 3 intervention groups (ie, 3 different vaccine
formulations) with the proportion with patent infection in a
control (placebo) group using a 1-sided Fisher exact test, for
a total of 3 comparisons. The Holm-Bonferroni procedure was
used to control the familywise error rate at .05.
RESULTS

Of 31 adults screened, 6 declined or were lost to follow-up
before enrollment, 5 were ineligible, and 20 (5 males and 5

Table 1. Incidence and Severity of Application Site, Respiratory and Gastrointestinal Solicited Adverse Reactions Following Application of 25 or 50 NaL3
by CHHI
25 NaL3 (n = 10)

50 NaL3 (n = 10)

Mild

Moderate

Severe

Mild

Moderate

Severe

No.

No.

No.

No.

No.

No.

8

1

–

10

–

–

10

–

–

8

2

–

Application site reactions
Rash
Pruritus
Pain

1

–

–

4

–

–

Tenderness

4

–

–

8

–

–

Swelling

2

–

1

4

1

–

Bruising

3

–

–

1

–

–

Respiratory reactions
Sore throat

2

2

–

7

–

–

Cough

2

2

–

7

–

–

Gastrointestinal reactions
Abdominal bloating

4

3

–

4

2

–

Abdominal pain

5

3

–

3

2

–

Nausea

3

2

–

3

2

–

Vomiting

1

2

–

–

–

–

Diarrhea

3

2

–

5

–

–

Flatulence

6

–

–

1

1

–

Data are number of participants experiencing an event. Participants with more than 1 occurrence of the same adverse reaction are recorded only once, at the maximum severity experienced.
Abbreviation: CHHI, controlled human hookworm infection.

females in each of the 2 cohorts) met eligibility criteria and
were enrolled (Supplementary Figure 1). Reasons for exclusion
were concomitant medical diagnoses such as irritable bowel
syndrome, Hashimoto’s thyroiditis, and iron deficiency anemia.
The median age of enrolled participants (range) was 25 (19–45)
years. Two participants in the 50 NaL3 cohort agreed to participate in an IRB-approved substudy and were not treated with
albendazole but have remained infected to serve as donors of
fecal samples, from which N. americanus eggs will be produced
for future HVCM studies. Mean percentages of residual larvae
were 5.60% and 5.40% for the 25 and 50 NaL3 cohorts, respectively (P = .56, Wilcoxon rank-sum test).
Safety of CHHI

Application of NaL3 to healthy, hookworm-naïve adults was
well tolerated. No participants were withdrawn or required early
treatment due to adverse events or discomfort (1 participant in
Cohort 1 withdrew early and was treated with albendazole on
day 63 due to moving unexpectedly from the area). Common
reactions consisted of early skin reactions at NaL3 application
sites and later gastrointestinal symptoms. NaL3 application
site reactions were mostly mild to moderate rash and pruritus
(Table 1). Rash occurred in 9/10 and 10/10 participants in the 25
and 50 NaL3 cohorts, respectively, and ranged from maculopapular to vesicular (Figure 1). Rashes were mild in severity, except
for 1 moderate case in the 25 NaL3 cohort; topical corticosteroids were used in 6/20 participants for symptom relief. Onset of
rash was typically noted immediately upon removal of the gauze
pad following NaL3 application and lasted a median (range)

of 26 (4–69) days. Residual skin hyperpigmentation occurred
in 3 participants in the 50 NaL3 cohort and lasted a median of
107 days after resolution of the rash; in 2 cases, the hyperpigmentation was still present, albeit fading, at the final visit.
Gastrointestinal complaints were common (Table 1) and
occurred primarily after week 4 p.i. (Figure 2). The incidence
and timing of these symptoms were not significantly different
between the 2 dose cohorts (Supplementary Table 1). Increased
flatulence (7/10 in the 25 NaL3 cohort and 3/10 in the 50 NaL3
cohort), abdominal bloating (7/10 in both cohorts), and abdominal pain (8/10 in the 25 NaL3 cohort and 5/10 in the 50 NaL3
cohort) were the most common gastrointestinal complaints, all of
which were mild or moderate in severity. Four episodes of vomiting occurred in 3 participants in the 25 NaL3 cohort, although

A

B

Figure 1. Representative images of rash induced by application of NaL3 to the
forearm. A, Day 7 postapplication of 25 NaL3. B, Day 35 postapplication of 50 NaL3.
Hookworm Vaccination-Challenge Model • OFID • 3
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Number of events per day
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0
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5

0

3
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0
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14
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63
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Week postinfection

Figure 2. Prevalence of gastrointestinal symptoms by study week. Bar graph represents sum of participants in each dose cohort who experienced abdominal pain, abdominal bloating, nausea, vomiting, or diarrhea that was assessed as being related to controlled human hookworm infection. A, 25 NaL3 cohort. B, 50 NaL3 cohort.

none were considered related to CHHI. Other solicited adverse
events possibly related to infection with N. americanus included
respiratory symptoms due to larvae transiting through the lungs
and upper airways. Cough was reported by 6 and 4 participants
in the 25 and 50 NaL3 cohorts, respectively, while 4 and 7 participants complained of transient sore throat. The median onset of
respiratory symptoms (range) was 2 (8–43) days p.i.
Patent Infection and Intensity of Infection

Fifty NaL3 resulted in significantly more (9/10 vs 3/10) participants developing patent N. americanus infection, as determined
by saline flotation, than 25 NaL3 (P = .02), whereas 40% (n = 4)
of the 25 NaL3 group had patent infection, as determined by
qPCR, compared with 90% (n = 9) with 50 NaL3 (Figure 3).
The difference in the proportion with patent infection when
measured by qPCR between the 2 groups was just above the
level of significance (P = .06). A significant difference was
found between the 25 and 50 NaL3 groups in the distribution of
time to patency based on Kaplan-Meier curves (P = .04) when
assessed by qPCR, although not by saline flotation (P = .11).
Two participants in the 25 NaL3 cohort had eggs in feces quantifiable by MM, ranging from 16.67 to 33.33 EPG (Figure 4A).
Four of the 25 NaL3 cohort with patent infections, as determined
by qPCR, had quantifiable eggs in feces, also by qPCR (range,
1.5–123.6 EPG). Nine in the 50 NaL3 cohort had quantifiable
4 • OFID • Diemert et al
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egg counts by both MM and qPCR, ranging from 16.33 to 166.66
EPG by MM and from 1.2 to 373.2 EPG by qPCR (Figure 4).
When compared by study day, there were no statistically significant differences in distribution of EPG or “visit-to-visit” changes
in EPG between dose groups (Supplementary Table 2).
There were no statistically significant differences in the distribution of time to patency or intensity of infection by either MM
or qPCR. MM was slightly more accurate than qPCR by ROC
curve analysis. Using saline flotation as the gold standard, the
value of the area under the curve (AUC) for detecting fecal eggs
using the MM (AUCMM, 0.97) was greater than that for qPCR
(AUCqPCR, 0.88), although the difference was not significant
(P = .16) (Figure 5).
Eosinophil Counts

Those who received 50 NaL3 had a more rapid and greater
increase in eosinophil count that declined faster than in those
who received 25 NaL3 (Figure 6). Starting at 49 and 42 p.i.,
median eosinophil levels in volunteers in the 25 and 50 NaL3
dose groups increased significantly (both P < .02) above the
upper limit of the normal range and remained high until treatment. Eosinophilia peaked 56 and 42 days p.i. for the 25 and 50
NaL3 groups, respectively. When compared on each study day,
there were no statistically significant differences in distribution of eosinophil counts between dose groups (Supplementary

1.0

0.9

0.8

Probability of nonpatency

0.7

Saline Flotation_25L3
qPCR_25L3
Saline Flotation_50L3
qPCR_50L3

0.6

0.5

0.4

0.3
Saline f lotation P = .11
qPCR P = .04

0.2

0.1
42

49

56

63

77

70

84

91 94 98 101 105

112

119

126

136 140 143

Study Day

Figure 3. Time to patency for controlled Necator americanus infection as shown by Kaplan-Meier curves for volunteers exposed to either 25 N. americanus third-stage
larvae (NaL3), as shown by the red line, or 50 NaL3, as shown by the blue line. Solid lines represent the proportion of individuals in the dose group with patent N. americanus
infection, as detected by saline flotation, while dotted lines represent the proportion with patent infection, as determined by quantitative polymerase chain reaction. Crosses
indicate censored data. Abbreviation: qPCR, quantitative polymerase chain reaction.

A

B
40

100
25L3
50L3

25L3
50L3

20

EPG

EPG

50

0

0

–50

Study day

14
0

11
2

98

84

77

63

42

13
146
140
3

9
12
6

11

84
91
94
9
108
10 1
5
11
2

77

70

63

56

49

42

–20

Study day

Figure 4. Eggs per gram (EPG) of feces, as determined by the McMaster (A) and quantitative polymerase chain reaction (B) methods for controlled human hookworm infection with an inoculum of 25 Necator americanus third-stage larvae (NaL3), as shown by the red line, or 50 NaL3, as shown by the blue line. Each dot represents the median
EPG of the inoculum group by study day, and the solid lines show the trend in EPG for each inoculum group using locally weighted regression. The gray shading shows the
upper and lower boundaries of the 95% confidence interval around the trend line.
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MM AUC = .9722
qPCR AUC = .8826
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False-positive fraction

Figure 5. Receiver operator characteristic curves comparing the accuracy (area under the curve) of quantitative polymerase chain reaction with the conventional McMaster
method to indicate patency (eggs in stool) from controlled human hookworm infection with 50 Necator americanus third-stage larvae (NaL3) using the saline flotation technique as the gold standard. Abbreviations: AUC, area under the curve; MM, McMaster; PCR, polymerase chain reaction.

Table 3). However, “visit-to-visit” changes in eosinophil count
declined significantly faster (P = .03) in the 50 NaL3 cohort
compared with the 25 NaL3 cohort from days 70 to 77.
Interaction Between Eosinophil Counts and NaL3 Dose on Time to
Patency

In a Cox regression model, neither NaL3 dose nor eosinophil count
significantly predicted the probability of patent N. americanus
infection (P > .05). In addition, 50 NaL3 resulted in a 2.72 times
(P = .15) or 2.55 times (P = .12) greater probability of patency than
25 NaL3, as determined by saline flotation or qPCR, respectively.
Eosinophil Count and Infection Intensity

Longitudinal fecal egg counts were analyzed using a generalized linear mixed-effects model with random intercept and an
unstructured covariance matrix. The response variable EPG
was assumed to have a Poisson distribution, and residual pseudo-likelihood was used as the estimation procedure. The dose
of NaL3 and the eosinophil count induced by each dose predicted intensity of infection (EPG) when quantified either by
MM or qPCR (P < .001). Parameters associated with EPG are
reported in Supplementary Table 4.
Power Calculations for HVCM

Assuming a rate of 90% patent hookworm infection, as observed
in the 50 NaL3 dose cohort in the current study, and a greater
6 • OFID • Diemert et al
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than 80% rate of protection in at least 1 of 3 vaccination groups
(eg, different doses or adjuvant formulations) compared with
controls who did not receive the hookworm vaccine, a sample
size of 48 (12 per group) would be sufficient to demonstrate the
efficacy of a prophylactic hookworm vaccine such as Na-GST-1
or Na-APR-1, at an alpha of 0.05/3 and a power of 87.7%.
DISCUSSION

This manuscript describes the first administration of NaL3
obtained from a human donor and manufactured under cGMP
conditions to infect hookworm-naïve volunteers in a clinical
trial in the United States. Moreover, this is the first CHHI trial
to be conducted under an IND with the FDA. As such, the
results enable us to use CHHI to test the efficacy of experimental hookworm vaccines in an HVCM under the existing US regulatory framework.
Both the 25 and 50 NaL3 inocula were safe and well tolerated, with application site and gastrointestinal reactions being
the most common adverse events in both groups. Of note, skin
reactions (mild to moderate pruritus, pain, erythema, and rash)
occurred in most participants, lasted several weeks in a minority, and in some participants resulted in residual hyperpigmentation. Interestingly, the dermatologic findings were more
significant and prolonged than reported in previous CHHI
studies [18, 19, 23]. Gastrointestinal complaints were mild to

2.0

Eosinophilia counts

1.5

1.0

0.5

25L3
50L3

0.0

0

14

35

42

49

56

63

70

77

84

Study day

Figure 6. Peripheral eosinophil counts of volunteers infected with 25 Necator americanus third-stage larvae (NaL3) in red or 50 NaL3 in blue. Dots represent median
eosinophil counts by study day, and the lines show the trend of eosinophil counts for each cohort using locally weighted regression. The upper and lower boundaries of the
95% confidence interval around the trend line are depicted by the gray shading.

moderate in severity and coincided with onset of patency. All
participants stated that they would participate in the study
again if given the opportunity.
Fifty NaL3 induced a significantly higher proportion of patent N. americanus infections than 25 NaL3 and also resulted
in quantifiable fecal egg counts by conventional MM or qPCR.
One possible explanation for the lower rate of patency in the 25
NaL3 group is that fewer NaL3 applied to the forearm traversed
the dermis and lungs and succeeded in migrating to the intestine, or, if they did reach the intestine, they were too few in
number to have resulted in effective mating. Based on these
data, we estimate for an HVCM trial that 50 NaL3 would be sufficient to demonstrate the efficacy of an experimental vaccine
using only 48 individuals divided into 3 groups (eg, different
doses or formulations) compared with an unvaccinated control
group, with 12 volunteers per group (Supplementary Figure 2).
The current CHHI study enabled an unprecedented observation of the host response to N. americanus infection. As skin-penetrating nematodes, NaL3 have been thought to traverse the dermis
within 48–72 hours p.i., with 98% traversing the lungs within the
first 120 hours p.i., after which they undergo tracheo-esophageal migration and enter the lumen of the gastrointestinal tract
for the fourth molt [24]. As we have shown, marked eosinophilia
was observed in both dose groups, although 50 NaL3 resulted in

a significantly earlier onset, higher peak, and more rapid decline
than 25 NaL3. Eosinophilia during experimental hookworm
infection has long been thought to coincide with larvae traversing
lung parenchyma [13, 25]. However, as described in animal models [26], NaL3 may have already reached the gastrointestinal tract
by 14 days p.i., in which case development of eosinophilia would
be concomitant with initiation of blood feeding and recruitment
of inflammatory cells to feeding sites [25].
The current study allowed comparisons between conventional coprological methods such as the saline flotation and
McMaster techniques with novel molecular methods (qPCR) for
the detection of N. americanus eggs. Both conventional methods detected the same time to patency, while qPCR detected
more patent infections in the 25 NaL3 group than conventional
techniques. No difference was observed in measurements of
infection intensity by MM or qPCR. However, the MM method
was slightly more accurate than qPCR, as determined by ROC
analysis (Figure 5). The main advantage of qPCR is that frozen
fecal samples can be used, whereas conventional coprological
methods require fresh specimens.
The incorporation of CHHI into hookworm vaccine clinical
development would dramatically improve the efficiency of vaccine efficacy testing. Currently, efficacy studies for a preventative vaccine propose treating hookworm-infected volunteers in
Hookworm Vaccination-Challenge Model • OFID • 7
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endemic areas prior to vaccination and determining efficacy by
comparing incidence of reinfection or mean intensity of reinfection. Such a trial would require a sample size of approximately
1200 volunteers and last for several years [8]. However, an
HVCM trial would last only 3 months following completion of
vaccinations and require far fewer volunteers (eg, 12 adults per
group, with 1 group serving as unvaccinated infectivity controls),
such that multiple vaccine candidates or adjuvant formulations
could be assessed simultaneously to facilitate rapid downselection of the most promising product for phase 3 efficacy testing.
Our findings support the use of CHHI as a tool to assess
hookworm vaccine efficacy and provide the framework for
ensuring reproducible and accurate results that can be used to
justify regulatory applications for efficacy testing. Moreover, for
the concept of using controlled hookworm infection as a potential therapeutic for autoimmune and allergic diseases [12, 15,
23, 27], production of high-quality NaL3 in compliance with
cGMP and administration to study participants according to
current Good Clinical Practice will be required.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases
online. Consisting of data provided by the authors to benefit the reader,
the posted materials are not copyedited and are the sole responsibility of
the authors, so questions or comments should be addressed to the corresponding author.
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